{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:52:18Z","timestamp":1788274338925,"version":"build-2803163510"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA174650-09, 1U01CA233360-01, CA142746"],"award-info":[{"award-number":["CA174650-09, 1U01CA233360-01, CA142746"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-20-1-0342"],"award-info":[{"award-number":["W81XWH-20-1-0342"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ovarian cancer has long been known to be the deadliest cancer associated with the female reproductive system. More than 15% of ovarian cancer patients have a defective BRCA-mediated homologous recombination repair pathway that can be therapeutically targeted with PARP inhibitors (PARPi), such as Talazoparib (TLZ). The expansion of TLZ clinical approval beyond breast cancer has been hindered due to the highly potent systemic side effects resembling chemotherapeutics. Here we report the development of a novel TLZ-loaded PLGA implant (InCeT-TLZ) that sustainedly releases TLZ directly into the peritoneal (i.p.) cavity to treat patient-mimicking BRCA-mutated metastatic ovarian cancer (mOC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>InCeT-TLZ was fabricated by dissolving TLZ and PLGA in chloroform, followed by extrusion and evaporation. Drug loading and release were confirmed by HPLC. The <jats:italic>in vivo<\/jats:italic> therapeutic efficacy of InCeT-TLZ was carried out in a murine <jats:italic>Brca2<jats:sup>-\/-<\/jats:sup>p53<jats:sup>R172H\/-<\/jats:sup>Pten<jats:sup>-\/-<\/jats:sup><\/jats:italic> genetically engineered peritoneally mOC model. Mice with tumors were divided into four groups: PBS i.p. injection, empty implant i.p. implantation, TLZ i.p. injection, and InCeT-TLZ i.p. implantation. Body weight was recorded three times weekly as an indicator of treatment tolerance and efficacy. Mice were sacrificed when the body weight increased by 50% of the initial weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Biodegradable InCeT-TLZ administered intraperitoneally releases 66 \u03bcg of TLZ over 25 days. <jats:italic>In vivo<\/jats:italic> experimentation shows doubled survival in the InCeT-TLZ treated group compared to control, and no significant signs of toxicity were visible histologically in the surrounding peritoneal organs, indicating that the sustained and local delivery of TLZ greatly maximized therapeutic efficacy and minimized severe clinical side effects. The treated animals eventually developed resistance to PARPi therapy and were sacrificed. To explore treatments to overcome resistance, <jats:italic>in vitro<\/jats:italic> studies with TLZ sensitive and resistant ascites-derived murine cell lines were carried out and demonstrated that ATR inhibitor and PI3K inhibitor could be used in combination with the InCeT-TLZ to overcome acquired PARPi resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to intraperitoneal PARPi injection, the InCeT-TLZ better inhibits tumor growth, delays the ascites formation, and prolongs the overall survival of treated mice, which could be a promising therapy option that benefits thousands of women diagnosed with ovarian cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1175617","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:44:47Z","timestamp":1683611087000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Shicheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Needa","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merline","family":"Senat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryanna","family":"Testino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M.","family":"Dinulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1167088","article-title":"Editorial: methods in gynecological oncology","volume":"13","author":"Perelli","year":"2023","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":":82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum\u2212based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"175071","DOI":"10.1016\/j.ejphar.2022.175071","article-title":"Tackling drug resistance in ovarian cancer with epigenetic targeted drugs","volume":"927","author":"Zhao","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am J Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05690-4","article-title":"Use of fertility treatments in BRCA1\/2 mutation carriers and risk for ovarian and breast cancer: a systematic review","volume":"302","author":"Huber","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"B8","unstructured":"BRCA gene mutations: cancer risk and genetic testing2020"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1133472","article-title":"Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: clinical outcomes and mechanistic insights","volume":"11","author":"Ragupathi","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2741\/4230","article-title":"The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers","volume":"19","author":"Paul","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.026","article-title":"A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer","volume":"171","author":"Blanc-Durand","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B12","article-title":"SEER cancer statistics review","volume-title":"SEER cancer statistics review (CSR) 1975-2017","author":"Howlader N","year":"2020"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13697137.2023.2189583","article-title":"Treatment of women with BRCA mutation","author":"Depypere","year":"2023","journal-title":"Climacteric"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2009.02.001","article-title":"The contribution of BRCA1 and BRCA2 to ovarian cancer","volume":"3","author":"Ramus","year":"2009","journal-title":"Mol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.02.017","article-title":"Two decades beyond BRCA1\/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy","volume":"137","author":"Walsh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":":3408","DOI":"10.3390\/cells10123408","article-title":"Biomarkers of central nervous system involvement from epithelial ovarian cancer","volume":"10","author":"Scotto","year":"2021","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00170","article-title":"Poly(ADP-Ribose)Polymerase (PARP) inhibitors and radiation therapy","volume":"11","author":"Jannetti","year":"2020","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0587-4","article-title":"PARP inhibitors in the treatment of triple-negative breast cancer","volume":"57","author":"Geenen","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100049","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod Pathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-019-0154-9","article-title":"Advances and perspectives of PARP inhibitors","volume":"8","author":"Yi","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discovery"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e22286","DOI":"10.1002\/jbt.22286","article-title":"BMN 673 (talazoparib): a potent PARP inhibitor for triple negative breast cancer with different genetic profile","volume":"33","author":"Guney Eskiler","year":"2019","journal-title":"J Biochem Mol Toxicol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAnessPARP1 inhibitors trigger antitumor immunity","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S200524","article-title":"Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer","volume":"11","author":"Jiang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","article-title":"Poly (ADP-ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond","volume":"20","author":"Boussios","year":"2020","journal-title":"Drugs R D"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01304","article-title":"Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant","volume":"38","author":"Litton","year":"2020","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.09.023","article-title":"Auto-induction of intestinal first-pass effect related time-dependent pharmacokinetics of artemisinin rather than dihydroartemisinin","volume":"110","author":"Chai","year":"2021","journal-title":"J Pharm Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.2147\/OTT.S184971","article-title":"Evidence to date: talazoparib in the treatment of breast cancer","volume":"12","author":"Exman","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2020.1381","article-title":"Talazoparib versus chemotherapy in patients with HER2-negative advanced breast cancer and a germline BRCA1\/2 mutation enrolled in asian countries: exploratory subgroup analysis of the Phase III EMBRACA trial","volume-title":"Cancer Res Treat","author":"Lee","year":"2021"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/15685551.2021.2003995","article-title":"Fabrication, characterization and toxicity evaluation of chemically cross linked polymeric network for sustained delivery of metoprolol tartrate","volume":"24","author":"Sumaira","year":"2021","journal-title":"Des Monomers Polym"},{"key":"B39","doi-asserted-by":"publisher","first-page":":1420","DOI":"10.3390\/cancers14061420","article-title":"PARP inhibitors resistance: mechanisms and perspectives","volume":"14","author":"Giudice","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses De novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0317","article-title":"PARP inhibition suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine differentiation in castration-resistant prostate cancer","volume":"25","author":"Liu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1494","article-title":"Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer","volume":"78","author":"Carey","year":"2018","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":":1807","DOI":"10.3390\/cancers14071807","article-title":"Combinations of ATR, Chk1 and Wee1 inhibitors with olaparib are active in olaparib resistant Brca1 proficient and deficient murine ovarian cells","volume":"14","author":"Chiappa","year":"2022","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0568","article-title":"Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance","volume":"28","author":"Serra","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"106162","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","article-title":"Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition","volume":"71","author":"Haynes","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11523-020-00701-5","article-title":"Safety, pharmacokinetics, and clinical activity of adavosertib in combination with chemotherapy in Asian patients with advanced solid tumors: phase ib study","volume":"15","author":"Kato","year":"2020","journal-title":"Target Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ijrobp.2014.10.041","article-title":"Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy","volume":"91","author":"Kumar","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41598-020-79663-7","article-title":"Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.06.013","article-title":"Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes","volume":"12","author":"Ince","year":"2007","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e80314","DOI":"10.1371\/journal.pone.0080314","article-title":"Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes","volume":"8","author":"Merritt","year":"2013","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1158\/2159-8290.CD-20-0818","article-title":"Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy","volume":"11","author":"Iyer","year":"2021","journal-title":"Cancer Discovery"},{"key":"B57","doi-asserted-by":"publisher","first-page":":15","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2019","journal-title":"Med (Kaunas)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-0620-8_3","article-title":"Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications","volume":"812","author":"Vaupel","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00353","article-title":"Nanoformulation of talazoparib delays tumor progression and ascites formation in a late stage cancer model","volume":"9","author":"Baldwin","year":"2019","journal-title":"Front Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":":PO.20.00439","DOI":"10.1200\/PO.20.00439","article-title":"Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (Olaparib combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1245\/s10434-021-10922-1","article-title":"Malignant bowel obstruction management over time: are we doing anything new? a current narrative review","volume":"29","author":"Shariff","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.288","article-title":"Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies","volume":"117","author":"Mita","year":"2017","journal-title":"Br J Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/jcm10071437","article-title":"Recent developments in nanomedicine for pediatric cancer","volume":"10","author":"Yang","year":"2021","journal-title":"J Clin Med"},{"key":"B66","article-title":"Brain metastases from epithelial ovarian cancer. the Hellenic cooperative oncology group (HeCOG) experience and review of the literature","volume":"25","author":"Pectasides","year":"2005","journal-title":"Anticancer Res"},{"key":"B67","article-title":"Brain metastases from epithelial ovarian cancer: overview and optimal management","volume":"29","author":"Pietzner","year":"2009","journal-title":"Anticancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1175617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:44:54Z","timestamp":1683611094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1175617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":67,"alternative-id":["10.3389\/fonc.2023.1175617"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1175617","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"article-number":"1175617"}}